Current Opinion in HIV & AIDS:
Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
David Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery at Duke University Medical Center, USA. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV-1 vaccines. He started working with HIV-1 in 1985 while in the Department of Pathology at Vanderbilt University Medical Center, where he developed one of the earliest high throughput assays to measure HIV-1 neutralization. He moved to Duke in 1993, where he continued to study the antibody response in HIV-1 infected people and in SIV and SHIV infected non-human primates with the aim of assessing the protective value of antibodies, identifying key epitopes and designing sensitive, quantitative and validated assays. For the past two decades his laboratory has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines. His laboratory is funded by the National Institutes of Health as a member of the HIV Vaccine Trials Network (HVTN), the Center for HIV/AIDS Vaccine Immunology (CHAVI) and the Primate Core Immunology/Virology Laboratories. His laboratory also receives funding from the Bill and Melinda Gates Foundation as a member of the Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 300 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.
John Mascola is the Deputy Director of the Vaccine Research Center (VRC) of the National Institutes of Allergy and Infectious Diseases, NIH, and is Chief of the BSL3 Core Virology Laboratory. His research interests include HIV-1 virology, humoral immunity and vaccine development.
Dr Mascola received his medical degree from Georgetown University, USA in 1985 and is board certified in infectious diseases. He performed post-doctoral research at the Walter Reed Army Institute of Research where he began studies of antibody-mediated neutralization of HIV-1 and protective immune responses. Since joining the VRC in 2000, Dr Mascola's laboratory has continued to focus on mechanisms of virus neutralization and elucidating viral epitopes targeted by neutralizing antibodies in order to inform the design of antibody-based vaccines. His work at the VRC also includes preclinical SIV pathogenesis and vaccine studies and clinical trials of novel HIV vaccine candidates.
Dr Mascola holds concurrent appointments as adjunct professor of medicine at the Uniformed Services University of the Health Sciences and attending physician in the Department of Infectious Diseases at the National Naval Medical Center.